These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17073688)

  • 41. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IgE antibody-specific activity in human allergic disease.
    Hamilton RG; MacGlashan DW; Saini SS
    Immunol Res; 2010 Jul; 47(1-3):273-84. PubMed ID: 20066506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omalizumab.
    Easthope S; Jarvis B
    Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of omalizumab on markers of inflammation in patients with allergic asthma.
    Holgate S; Smith N; Massanari M; Jimenez P
    Allergy; 2009 Dec; 64(12):1728-36. PubMed ID: 19839977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Omalizumab: Anti-IgE therapy in allergy.
    Kopp MV
    Curr Allergy Asthma Rep; 2011 Apr; 11(2):101-6. PubMed ID: 21243454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omalizumab: not only for asthma.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of omalizumab from a health plan perspective.
    Belliveau PP; Lahoz MR
    J Manag Care Pharm; 2005; 11(9):735-45. PubMed ID: 16300417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review.
    Buhl R
    Respir Med; 2003 Feb; 97(2):123-9. PubMed ID: 12587961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anti-immunoglobulin E, a monoclonal antibody to treat respiratory disorders].
    Cabrera-Navarro P
    Arch Bronconeumol; 2006 May; 42(5):241-5. PubMed ID: 16740240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
    D'Amato G; Salzillo A; Piccolo A; D'Amato M; Liccardi G
    Ther Clin Risk Manag; 2007 Aug; 3(4):613-9. PubMed ID: 18472983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
    Corren J; Casale T; Deniz Y; Ashby M
    J Allergy Clin Immunol; 2003 Jan; 111(1):87-90. PubMed ID: 12532101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine].
    Pfaar O; Klimek L
    HNO; 2007 Dec; 55(12):981-90; quiz 991-2. PubMed ID: 17992493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.